Table 3.
Treatment patterns among patients with plasmacytoma (P-bone: Bone plasmacytoma; P-EM:Extramedullary plasmacytoma)
| Site of plasmacytoma | Surgery + Radiation | Neither Surgery nor Radiation | Radiation alone | Surgery alone |
|---|---|---|---|---|
| P-Bone | 886 (25.1%) | 373 (10.6%) | 1948 (55.2%) | 321 (9.1%) |
| P-EM | 528 (34.6%) | 135 (8.8%) | 543 (35.5%) | 322 (21.1%) 95 (2.4%) |
| P-EM subgroups (n=1528) | ||||
| Breast | 6 (37.5%) | 0 (0.0%) | 5 (31.3%) | 5 (31.3%) |
| Cardiac/Mediastinum | 3 (13.6%) | 5 (22.7%) | 13 (59.1%) | 1 (4.5%) |
| Central Nervous System | 64 (55.7%) | 5 (4.3%) | 20 (17.4%) | 26 (22.6%) |
| Digestive System/Hepatobiliary | 14 (11.5%) | 22 (18.0%) | 30 (24.6%) | 56 (45.9%) |
| Endocrine System | 7 (20.6%) | 2 (5.9%) | 13 (38.2%) | 12 (35.3%) |
| Eye/Orbit | 7 (23.3%) | 0 (0.0%) | 14 (46.7%) | 9 (30.0%) |
| Female Reproductive System | 3 (21.4%) | 1 (7.1%) | 3 (21.4%) | 7 (50.0%) |
| Genitourinary | 3 (10.7%) | 4 (14.3%) | 9 (32.1%) | 12 (42.9%) |
| Male Reproductive System | 1 (8.3%) | 0 (0.0%) | 0 (0.0%) | 11 (91.7%) |
| Lymph Node/Spleen | 22 (37.9%) | 10 (17.2%) | 15 (25.9%) | 11 (19.0%) |
| Pulmonary | 1 (1.2%) | 18 (21.4%) | 37 (44.0%) | 28 (33.3%) |
| Salivary Glands | 10 (58.8%) | 0 (0.0%) | 3 (17.6%) | 4 (23.5%) |
| Connective/Soft Tissue | 75 (25.4%) | 44 (14.9%) | 126 (42.7%) | 50 (16.9%) |
| Upper Aero-Digestive Tract | 312 (45.8%) | 24 (3.5%) | 255 (37.4%) | 90 (13.2%) |